^
Association details:
| Biomarker: | MSLN expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | LNK101 (CD3 agonist, Mesothelin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1384 LNK101, a highly differentiated T-cell engager (TCE) targeting CD3 and mesothelin (MSLN) in solid tumors
Published date:
11/04/2023
Excerpt:
In vitro results indicate that LNK101 binds specifically to MSLN-expressing cells...and has potent antitumor activity. In cynomolgus monkeys, LNK101 is tolerated and shows pharmacologic activity. LNK101 is a promising novel treatment for MSLN-expressing solid tumors.
DOI:
10.1136/jitc-2023-SITC2023.1384
